CHIR-124 Chemical Structure
PD 0332991 is a highly selective inhibitor of Cdk4/cyclin D1 and Cdk6/cyclin D2 with IC50 of 11 nM and 16 nM, respectively.
SNS-032 (BMS-387032) is a potent and selective cyclin-dependent kinases (CDK) 9, 7 and 2 inhibitor with IC50 of 4, 62 and 38 nM for CDK9, CDK2/cyclin A and CDK7/Cyclin H.
Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective inhibitor of the cyclin-dependent kinases with IC50 of 0.65, 0.7, 0.7 and 0.16 μM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p53, respectively.
Flavopiridol (Alvocidib) is a pan-cdk inhibitor. Flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC50 in the region of 100 nM) and tumour cell growth in vitro (typical IC50 in the region of 100 nM). Flavopiridol inhibited rhabdoid cell growth (IC50 of 200nmol/L).
JNJ-7706621 is a novel, potent, and broad-spectrum inhibitor of CDK and Aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B with IC50 of 9 nM, 4 nM, 3 nM and 11 nM, respectively.
PHA-793887 is a novel pan-cdk inhibitor, including cdk1, cdk2, cdk4, cdk5, cdk7, and cdk9 with IC50 in the 5 to 140 nM range.
AT7519 is a kinase inhibitor with IC50 of 0.19, 0.044, 0.51, 0.067, 0.66 and 0.018 μM for CDK1/cyclinB, CDK2/CyclinA, CDK2/Cyclin E, CDk4/CyclinD1, CDK6/Cyclin D3, CDk5/p35.
AZD7762 is a novel checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2, respectively.
BS-181 is a highly selective cyclin-dependent kinase (CDK) inhibitor of CDK7 activity with IC50 of 21 nM.
CHIR-124 is a novel and potent chk1 inhibitor with an IC50 of 0.3 nM. Chk1 kinase is a critical regulator of both the S and G2/M phase cell cycle checkpoints in response to DNA damage. It has been shown that inhibitors of chk1 can selectively sensitize tumor cells with mutant p53 to genotoxic agents. CHIR-124 is a quinolone-based small molecule that is structurally unrelated to other known inhibitors of chk1. CHIR-124 interacts synergistically with camptothecin in causing growth inhibition in MDA-MB-435 cells as determined by isobologram analysis. In HCT116 human colon carcinoma cells, CHIR-124 increased the effect of SN-38, an active metabolite of irinotecan, in a sequence-dependent manner, with the highest induction of mitotic catastrophe and apoptosis seen when CHIR-124 was given sequentially after SN-38 pretreatment. More importantly, the enhancement of cell death by CHIR-124 was markedly increased in isogenic p53-null and p21-null HCT116 cells. [1][2]
| Molecular Weight (WM): | 419.91 |
|---|---|
| Formula: | C23H22ClN5O |
| CAS No.: | 405168-58-3 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
A collection of 864 bioactive compounds
A collection of 481 inhibitors
A collection of 194 kinase inhibitors
A collection of 85 tyrosine kinase inhibitors.
A collection of 426 FDA approved drugs
A collection of 139 natural products
A collection of 40 chemotherapeutic agents
A unique collection of 17 small molecule modulators
A unique collection of 47 small molecule inhibitors
A unique collection of 63 GPCR small molecules
Keywords:buy CHIR-124 | CHIR-124 supplier | purchase CHIR-124 | CHIR-124 cost | CHIR-124 manufacturer | order CHIR-124 | CHIR-124 distributor